CARY, N.C., July 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, August 10, 2026, at 8:30 a.m. ET to report second quarter financial results and discuss recent business highlights.
The conference call can be accessed by phone by utilizing the following
registration link
which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Investor Relations section of Heron’s website at
www.herontx.com
. An archive of the teleconference and webcast will also be made available on Heron’s website for 60 days following the call.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit
www.herontx.com
.
Forward-looking Statements
This news release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.
Investor Relations and Media Contact:
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
iduarte@herontx.com
858-251-4400
View the Zacks #1 Rank List
Heron Therapeutics to Report Second Quarter 2026 Financial Results on August 10
Heron Therapeutics will host a conference call on August 10, 2026, to discuss Q2 financial results and business updates.
Quiver AI Summary
Heron Therapeutics, Inc. announced a conference call and live webcast scheduled for August 10, 2026, at 8:30 a.m. ET to discuss its second quarter financial results and recent business developments. Participants can join by phone using a provided registration link or via webcast on the company's website, where an archive will be available for 60 days post-call. Heron Therapeutics is a biotechnology company dedicated to developing innovative therapies aimed at improving patient care in acute care and oncology. The press release also includes a caution regarding forward-looking statements, highlighting the inherent risks and uncertainties in their projections.
Potential Positives
Potential Negatives
FAQ
When is the Heron Therapeutics conference call scheduled?
The conference call is scheduled for Monday, August 10, 2026, at 8:30 a.m. ET.
How can I access the Heron Therapeutics conference call?
Participants can access the call via a registration link that provides dial-in details or through a live webcast on Heron’s website.
Where can I find the webcast of the conference call?
The webcast will be available under the Investor Relations section of Heron's website at www.herontx.com.
Will there be a recording of the conference call?
Yes, an archive of the teleconference and webcast will be available on Heron’s website for 60 days following the call.
What does Heron Therapeutics specialize in?
Heron Therapeutics is focused on developing and commercializing therapeutic innovations for improving medical care in acute care and oncology.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$HRTX Revenue
$HRTX had revenues of $34.7M in Q1 2026. This is a decrease of -26.71% from the same period in the prior year.
You can track HRTX financials on Quiver Quantitative's HRTX stock page.
You can access data on HRTX stock through the Quiver Quantitative API.
$HRTX Hedge Fund Activity
We have seen 69 institutional investors add shares of $HRTX stock to their portfolio, and 69 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
CARY, N.C., July 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, August 10, 2026, at 8:30 a.m. ET to report second quarter financial results and discuss recent business highlights.
The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Investor Relations section of Heron’s website at www.herontx.com . An archive of the teleconference and webcast will also be made available on Heron’s website for 60 days following the call.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com .
Forward-looking Statements
This news release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.
Investor Relations and Media Contact:
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
iduarte@herontx.com
858-251-4400
Read full article here »